NY-RHINOSTICS
11.3.2021 14:02:11 CET | Business Wire | Press release
In a Series A round, Covid Apollo announces its investment in Rhinostics, an early-stage company that provides a novel solution of enabling comfortable sample collection, rapid accessioning, and automated cap removal that can be linked to high throughput Covid-19 assays to remove wasted time, headcount and costs from laboratory workflows.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005325/en/
The Covid Apollo Project brings together expertise and capital to find and help scale the most promising Covid-19 diagnostic opportunities. Originally funded under the leadership of RA Capital Management, the Project includes Redmile Group, Samsara BioCapital, Perceptive Advisors, and Bain Capital. “Returning to school and work requires sustainable testing solutions,” said Parker Cassidy, Principal at RA Capital Management and a member of Covid Apollo’s Board of Directors. “Covid Apollo is focused on finding and accelerating the most promising COVID testing solutions to rebuild testing paradigms to address the unique challenges that the pandemic has presented. Rhinostics is a great example of a company bringing new technologies and thinking to a segment of the laboratory workflow that is antiquated and ripe for innovation and acceleration.”
“The investment in Rhinostics is right on mission for Covid Apollo. With our investments, we are aiming to accelerate technologies that can immediately impact COVID testing, which still struggles to meet testing demand, while also providing new tests and diagnostic tools and processes to enable ubiquitous testing in the future, providing not only better pandemic protection and monitoring but also new testing paradigms, that will empower patients and consumers to live safer and healthier lives,” commented Stefan Willemsen, Chief Executive Officer of Covid Apollo. He adds that “the team at Rhinostics has rapidly executed on its strategic plan to bring their products to market, already providing significant volumes of product into COVID testing laboratories. We are excited to support their next phase of growth, commercialization and global impact on the pandemic.”
Rhinostics spun out of Harvard University to commercialize a novel automated nasal collection device invented in partnership by two Harvard faculty, Mike Springer, Associate Professor of Systems Biology at Harvard Medical School; and Richard Novak, Lead Staff Engineer at the Wyss Institute for Biologically Inspired Engineering. The novel nasal collection swab has features that can increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. The product, registered as a Class I exempt medical device with the FDA, is currently being testing in several clinical trials, and the company is beginning an Emergency Use Authorization study comparing the RHINOstic™ swab to nasopharyngeal assays with a variety of polymerase chain reaction (PCR) assays. The product provides an immediate impact for increasing COVID testing efficiencies while being applicable to a broader range of respiratory viral, bacterial, and genetic testing using the PCR and next generation sequencing (NGS).
Cheri Walker, Chief Executive Officer of Rhinostics, commented, “We are thrilled to have Covid Apollo as a partner and investor to join our efforts to positively impact laboratory workflows and make a major impact on COVID testing volumes. Our missions are perfectly aligned to make a difference now. In addition, having Stefan as a board member will be a huge asset, as he is bringing more than 20 years of experience in leadership roles in the IVD industry to our fast-growing company, providing strategic advice and keen business insight. Together, we can change laboratory workflows for COVID and beyond.”
For decades there has been no innovation in viral collection and the process of moving samples into laboratories. The Rhinostics comfortable nasal swab solution brings new materials, better assay performance, dry shipment, instantaneous accessioning, and automated cap removal, all of which together can allow labs to significantly increase their sample throughput with no increase in footprint or staffing. This is changing the way laboratories think about their workflows.
About Covid Apollo Project
Covid Apollo Project aims to enable a safe and sustainable return to work and school by identifying, assembling, developing, and scaling the most promising COVID diagnostic opportunities. Covid Apollo was organized and funded under the leadership of RA Capital Management, a prominent biotechnology-focused investment firm, in collaboration with Redmile Group, Samsara BioCapital, Perceptive Advisors, and Bain Capital, and with legal support from Goodwin Procter. Covid Apollo is a funding founder of the $6M X-Prize competition to develop faster, cheaper and easier to use COVID testing methods at scale.
https://www.xprize.org/prizes/covidtesting
About Rhinostics
Rhinostics is revolutionizing laboratory workflows to link sample to result seamlessly. The company’s products improve sample collection performance while removing costs and time compared to traditional collection and intake. The products bring new materials, new collection types, rapid accessioning and automation to remove caps and move samples into high throughput workflows with little human intervention. The RHINOstic™ nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). The RHINOstic™ product is registered as Class I exempt medical device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005325/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kontoor Brands Unveils Helly Hansen Growth Strategy and 2030 Financial Targets2.9.2026 08:30:00 CEST | Press release
Kontoor Brands, Inc. (NYSE: KTB) today announced Helly Hansen’s long-term growth strategy and 2030 financial targets, which Kontoor Brands will present at the Helly Hansen® Investor Day later today. The plan is designed to scale Helly Hansen globally while significantly expanding its profitability through 2030. "With 150 years of technical heritage and an authentic right to win globally, Helly Hansen is a brand with tremendous long-term growth potential," said Scott Baxter, Chief Executive Officer and Chairman of the Board of Kontoor Brands. "Strong alignment between our teams has allowed us to integrate quickly and move straight to executing against the opportunity ahead. Our sustained investment in Helly Hansen will be a catalyst for its next phase of growth, and we are confident in our ability to deliver significant value for our consumers, employees and shareholders for years to come." A Focused Growth Strategy: To deliver against these targets, Helly Hansen’s growth is anchored in
Vara Receives World-First CE Certification for Autonomous AI in Breast Cancer Screening2.9.2026 08:00:00 CEST | Press release
Vara has received CE certification under the EU Medical Device Regulation (Class IIb) for autonomous triage in organised breast cancer screening – the first breast AI certified anywhere to report screening examinations as normal without radiologist review. In autonomous triage, examinations the system classifies as clearly normal can be reported by AI without a radiologist reading them; every other examination continues to be read by at least one radiologist. This deployment mode is intended for organised population screening, where a shrinking radiologist workforce is straining programmes that still read every mammogram twice. The certification has only been possible because Vara has developed a safety system that supervises the autonomous use of its AI models. "What made this possible is not the AI model alone," said Stefan Bunk, CTO and co-founder of Vara. "It is based on seven years of continuous monitoring of how our AI performs in the real world, on every single case. That experi
Phison Expands European Operations with Regional Office and Executive Appointments2.9.2026 08:00:00 CEST | Press release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, today announced the expansion of its European operations with the opening of its inaugural local entity in Eschborn, Germany, and the appointments of Ingvar Ersson as GM & President, EMEA, and Antony Zukowski as Regional Director, EMEA, for Phison Electronics Europe GmbH. The expansion strengthens Phison's investment in Europe and reinforces its commitment to supporting customers and partners as demand for AI infrastructure, enterprise storage and next-generation data center technologies continues to grow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901302026/en/ The extended organization will execute a regional go-to-market strategy that combines direct enterprise engagement with a focused ecosystem of distributors, system integrators and strategic partners to accelerate adoption of Phison's Pascari enterprise SSD portfolio.
Goku Technologies Chooses SS&C for Fund Services2.9.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Singapore Goku Technologies Pte. Ltd., an AI-driven quantitative investment manager, has chosen SS&C as its fund services provider. The firm, with offices in Shanghai and Singapore, employs systematic trading strategies to invest in equities across Asia, with USD4 billion in assets under management. SS&C GlobeOp will provide fund administration services for the Goku Technologies Master Fund. The fund operates a high-volume trading strategy with substantial daily trading activity. SS&C will support the fund through a comprehensive suite of services including fund accounting and investor services, helping Goku Technologies build a scalable operating model. “As our business has grown, so have our demands on our trading and operational framework,” said Ken Chung, CEO of Singapore Goku Technologies. “We are building an institutional quality operations infrastructure, so we needed a provider capable of supporting a high-vol
Boomi Delivers the Critical Infrastructure That Brings Control to Enterprise AI2.9.2026 03:00:00 CEST | Press release
Govern AI agents, optimize token spend, and mitigate security risk to operationalize AI at scale Boomi, the data activation company for AI, today announced major platform innovations designed to solve critical barriers to enterprise AI adoption. At the core of these updates is Boomi’s Agent Control Plane, AI-native infrastructure that securely connects AI agents to core business systems, provides governance over agent activity, and controls runaway AI costs. This critical infrastructure runs flexibly across public cloud, the customer’s own cloud (VPC), or on-premises, directly supporting data and digital sovereignty, and giving organizations greater operational control over their AI estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901851538/en/ Boomi Delivers the Critical Infrastructure That Brings Control to Enterprise AI Key Takeaways Boomi’s Agent Control Plane provides the critical AI-native infrastructure that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom